source
- Eli Lilly to acquire Calytrix Bio for up to $1.5 billion to add blood-cancer assetsEli Lilly announced it will acquire privately held Calytrix Bio in a deal valued at up to $1.5 billion in cash. The acquisition is Lilly’s 14th buyout this year and adds a blood-cancer program to…
- Eli Lilly makes 14th acquisition of 2026, buying a blood-cancer biotechEli Lilly announced it has acquired a blood‑cancer focused biotechnology company, marking its 14th acquisition in 2026. The deal reflects Lilly’s aggressive expansion strategy, funded by strong sa…